Karyopharm Therapeutics (KPTI) Competitors $7.25 -0.70 (-8.81%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$7.28 +0.03 (+0.34%) As of 03/3/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KPTI vs. ATAI, GOSS, FHTX, ANNX, NMRA, OLMA, IMMP, AQST, DSGN, and HRTXShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Atai Life Sciences (ATAI), Gossamer Bio (GOSS), Foghorn Therapeutics (FHTX), Annexon (ANNX), Neumora Therapeutics (NMRA), Olema Pharmaceuticals (OLMA), Immutep (IMMP), Aquestive Therapeutics (AQST), Design Therapeutics (DSGN), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Atai Life Sciences Gossamer Bio Foghorn Therapeutics Annexon Neumora Therapeutics Olema Pharmaceuticals Immutep Aquestive Therapeutics Design Therapeutics Heron Therapeutics Atai Life Sciences (NASDAQ:ATAI) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings. Which has more risk and volatility, ATAI or KPTI? Atai Life Sciences has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Does the media prefer ATAI or KPTI? In the previous week, Karyopharm Therapeutics had 24 more articles in the media than Atai Life Sciences. MarketBeat recorded 26 mentions for Karyopharm Therapeutics and 2 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 0.88 beat Karyopharm Therapeutics' score of 0.28 indicating that Atai Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, ATAI or KPTI? Atai Life Sciences has higher earnings, but lower revenue than Karyopharm Therapeutics. Atai Life Sciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Life Sciences$331K760.43-$40.22M-$0.81-1.85Karyopharm Therapeutics$145.24M0.42-$143.10M-$15.29-0.47 Do analysts rate ATAI or KPTI? Atai Life Sciences presently has a consensus target price of $9.00, indicating a potential upside of 500.00%. Karyopharm Therapeutics has a consensus target price of $57.50, indicating a potential upside of 693.10%. Given Karyopharm Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Atai Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ATAI or KPTI more profitable? Atai Life Sciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Atai Life SciencesN/A -65.75% -52.71% Karyopharm Therapeutics -52.62%N/A -39.58% Does the MarketBeat Community prefer ATAI or KPTI? Karyopharm Therapeutics received 208 more outperform votes than Atai Life Sciences when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 66.47% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAtai Life SciencesOutperform Votes33366.47% Underperform Votes16833.53% Karyopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% Do institutionals & insiders hold more shares of ATAI or KPTI? 28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAtai Life Sciences and Karyopharm Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.05M$7.22B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-7.116.1524.9519.21Price / Sales0.42187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book-4.936.447.334.28Net Income-$143.10M$139.03M$3.18B$247.04M7 Day Performance-18.81%-5.52%-4.42%-4.36%1 Month Performance-22.31%-8.56%-6.07%-5.59%1 Year Performance-59.21%-14.59%11.42%3.39% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics4.1256 of 5 stars$7.25-8.8%$57.50+693.1%-59.2%$66.94M$145.24M-7.11380Analyst ForecastStock SplitAnalyst RevisionATAIAtai Life Sciences3.1275 of 5 stars$1.80-9.8%$9.00+401.4%-29.6%$301.21M$331,000.00-2.2280GOSSGossamer Bio4.2952 of 5 stars$1.31-6.8%$9.20+605.0%-14.5%$297.98MN/A-4.11180News CoverageFHTXFoghorn Therapeutics2.3526 of 5 stars$5.20-0.6%$13.17+153.2%-45.6%$288.67M$34.15M-2.70120Upcoming EarningsANNXAnnexon1.8542 of 5 stars$2.70-4.1%$15.80+486.3%-60.0%$287.26MN/A-2.5760Earnings ReportNews CoverageNMRANeumora Therapeutics3.6961 of 5 stars$1.76-2.5%$16.50+840.2%-92.2%$283.54MN/A-0.94108Earnings ReportUpcoming EarningsGap UpOLMAOlema Pharmaceuticals3.0536 of 5 stars$4.95-0.9%$28.75+481.4%-71.6%$283.41MN/A-2.2670Upcoming EarningsIMMPImmutep1.8402 of 5 stars$1.91-0.6%$8.50+345.3%-19.1%$278.02M$5.14M0.002,021Positive NewsAQSTAquestive Therapeutics1.6337 of 5 stars$3.03+0.5%$11.00+263.6%-37.5%$275.81M$58.90M-6.72160Positive NewsDSGNDesign Therapeutics2.1665 of 5 stars$4.81-2.1%$7.00+45.7%+58.0%$272.06MN/A-5.6540News CoverageHRTXHeron Therapeutics4.0189 of 5 stars$1.78+2.6%$5.67+219.2%-14.2%$269.97M$137.74M-9.86300Earnings ReportAnalyst RevisionNews CoverageGap Down Related Companies and Tools Related Companies Atai Life Sciences Competitors Gossamer Bio Competitors Foghorn Therapeutics Competitors Annexon Competitors Neumora Therapeutics Competitors Olema Pharmaceuticals Competitors Immutep Competitors Aquestive Therapeutics Competitors Design Therapeutics Competitors Heron Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPTI) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts